Format

Send to

Choose Destination
Hum Vaccin Immunother. 2014;10(11):3117-24. doi: 10.4161/21645515.2014.983003.

Potential for immunotherapy in soft tissue sarcoma.

Author information

1
a Section of Surgical Oncology; Division of Upper GI/General Surgery; Department of Surgery ; University of Southern California; Keck School of Medicine ; Los Angeles , CA USA.

Abstract

Soft tissue sarcomas (STS) are rare, heterogeneous tumors of mesenchymal origin. Despite optimal treatment, a large proportion of patients will develop recurrent and metastatic disease. For these patients, current treatment options are quite limited. Significant progress has been made recently in the use of immunotherapy for the treatment of other solid tumors (e.g. prostate cancer, melanoma). There is a strong rationale for immunotherapy in STS, based on an understanding of disease biology. For example, STS frequently have chromosomal translocations which result in unique fusion proteins and specific subtypes have been shown to express cancer testis antigens. In this review, we discuss the current status of immunotherapy in STS, including data from human studies with cancer vaccines, adoptive cell therapy, and immune checkpoint blockade. Further research into STS immunology is needed to help design logical, subtype-specific immunotherapeutic strategies.

KEYWORDS:

adoptive cell therapy; cancer vaccines; immune checkpoint blockade; immunotherapy; soft tissue sarcoma

PMID:
25625925
PMCID:
PMC4514087
DOI:
10.4161/21645515.2014.983003
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center